Cargando…

Seniors with Parkinson's Disease: Initial Medical Treatment

Parkinson's disease most often presents after age 60, and patients in this age group are best managed with levodopa therapy as the primary treatment modality. Unlike young-onset parkinsonism (onset <age 40), this older age group is much less prone to subsequent development of levodopa respon...

Descripción completa

Detalles Bibliográficos
Autor principal: Ahlskog, J. Eric
Formato: Texto
Lenguaje:English
Publicado: Korean Neurological Association 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024520/
https://www.ncbi.nlm.nih.gov/pubmed/21264196
http://dx.doi.org/10.3988/jcn.2010.6.4.159
_version_ 1782196801345945600
author Ahlskog, J. Eric
author_facet Ahlskog, J. Eric
author_sort Ahlskog, J. Eric
collection PubMed
description Parkinson's disease most often presents after age 60, and patients in this age group are best managed with levodopa therapy as the primary treatment modality. Unlike young-onset parkinsonism (onset <age 40), this older age group is much less prone to subsequent development of levodopa responsive instability (dyskinesias, fluctuations). When these problems do occur in seniors, they usually can be managed by medication adjustments. The treatment goal is to keep patients active and engaged; levodopa dosage should be guided by the patients' responses and not arbitrarily limited to low doses, which may compromise patients' lives.
format Text
id pubmed-3024520
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Korean Neurological Association
record_format MEDLINE/PubMed
spelling pubmed-30245202011-01-24 Seniors with Parkinson's Disease: Initial Medical Treatment Ahlskog, J. Eric J Clin Neurol Review Parkinson's disease most often presents after age 60, and patients in this age group are best managed with levodopa therapy as the primary treatment modality. Unlike young-onset parkinsonism (onset <age 40), this older age group is much less prone to subsequent development of levodopa responsive instability (dyskinesias, fluctuations). When these problems do occur in seniors, they usually can be managed by medication adjustments. The treatment goal is to keep patients active and engaged; levodopa dosage should be guided by the patients' responses and not arbitrarily limited to low doses, which may compromise patients' lives. Korean Neurological Association 2010-12 2010-12-31 /pmc/articles/PMC3024520/ /pubmed/21264196 http://dx.doi.org/10.3988/jcn.2010.6.4.159 Text en Copyright © 2010 Korean Neurological Association
spellingShingle Review
Ahlskog, J. Eric
Seniors with Parkinson's Disease: Initial Medical Treatment
title Seniors with Parkinson's Disease: Initial Medical Treatment
title_full Seniors with Parkinson's Disease: Initial Medical Treatment
title_fullStr Seniors with Parkinson's Disease: Initial Medical Treatment
title_full_unstemmed Seniors with Parkinson's Disease: Initial Medical Treatment
title_short Seniors with Parkinson's Disease: Initial Medical Treatment
title_sort seniors with parkinson's disease: initial medical treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024520/
https://www.ncbi.nlm.nih.gov/pubmed/21264196
http://dx.doi.org/10.3988/jcn.2010.6.4.159
work_keys_str_mv AT ahlskogjeric seniorswithparkinsonsdiseaseinitialmedicaltreatment